Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
  • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/06—Antiasthmatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/04—Antipruritics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
  • A61P31/06—Antibacterial agents for tuberculosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
  • A61P31/08—Antibacterial agents for leprosy
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/10—Antimycotics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
  • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
  • A61P31/18—Antivirals for RNA viruses for HIV
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/20—Antivirals for DNA viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/20—Antivirals for DNA viruses
  • A61P31/22—Antivirals for DNA viruses for herpes viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P33/00—Antiparasitic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P33/00—Antiparasitic agents
  • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P33/00—Antiparasitic agents
  • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
  • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/02—Antineoplastic agents specific for leukemia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/04—Immunostimulants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/08—Antiallergic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• This invention relates to imidazoquinoline compounds that have ether and sulfonamide or sulfamide functionality at the 1 -position, and to pharmaceutical compositions containing such compounds.
• a further aspect of this invention relates to the use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals, and in the treatment of diseases, including viral and neoplastic diseases.
• this invention provides imidazoquinoline-4-amine and tetrahydroimidazoquinoIine-4-amine compounds that have an ether and sulfonamide or sulfamide containing substituent at the 1 -position.
• the compounds are defined by Formulas (I) and (II), which are defined in more detail infra. These compounds share the general structural formula
• the compounds of Formulas (I) and (II) are useful as immune response modifiers due to their ability to induce cytokine biosynthesis and otherwise modulate the immune response when administered to animals. This makes the compounds useful in the treatment of a variety of conditions such as viral diseases and tumors that are responsive to such changes in the immune response.
• the invention further provides pharmaceutical compositions containing the immune response modifying compounds, and methods of inducing cytokine biosynthesis in an animal, treating a viral infection in an animal, and/or treating a neoplastic disease in an animal by administering a compound of Formula (I) or (II) to the animal.
• the invention provides methods of synthesizing the compounds of the invention and novel intermediates useful in the synthesis of these compounds. Detailed Description of the Invention
• Imidazoquinoline compounds of the invention which have ether and sulfonamide or sulfamide functionality at the 1 -position are represented by Formula (I):
• Ri is selected from the group consisting of: -R 4 -NR 3 -S0 2 -R 5 -alkyl;
• R 2 is selected from the group consisting of: -hydrogen; -alkyl; -alkenyl; -aryl;
• Y is -O- or -S(O)o- 2 -;
• R 3 is H, C LIO alkyl, or arylalkyl;
• each t is independently alkyl or alkenyl, which may be interrupted by one or more -O- groups; or R and R 4 can join together to form a ring;
• each R 5 is independently H, C]- 10 alkyl, or C2- 1 0 alkenyl;
• Re is a bond, alkyl, or alkenyl, which may be interrupted by one or more -O- groups;
• R 7 is C ⁇ _ 10 alkyl; or R 3 and R 7 can join together to form a ring; n is 0 to 4; and each R present is independently selected from the group consisting of Cj-io alkyl, Ci-io alkoxy, hydroxy, halogen and trifluoromethyl; or a pharmaceutically acceptable salt thereof.
• the invention also includes tetrahydroimidazoquinoline compounds that bear an ether and sulfanomide or sulfamide containing substituent at the 1 -position. Such tetrahydroimidazoquinoline compounds are represented by Formula (II):
• X is -CHR 5 -, -CHR 5 -alkyl-, or -CHR 5 -alkenyl-;
• Ri is selected from the group consisting of:
• R 2 is selected from the group consisting of:
• Y is -O- or -S(O)o- 2 -;
• R 3 is H, Ci-io alkyl, or arylalkyl; each R-j is independently alkyl or alkenyl, which may be interrupted by one or more -O- groups; or R 3 and R-t can join together to form a ring; each R 5 is independently H, Ci-io alkyl, or C 2 . 10 alkenyl;
• Re is a bond, alkyl, or alkenyl, which may be interrupted by one or more
• R 7 is Ci-io alkyl; or R 3 and R 7 can join together to form a ring; n is 0 to 4; and each R present is independently selected from the group consisting of Ci-io alkyl, C ⁇ - ⁇ 0 alkoxy, hydroxy, halogen, and trifluoromethyl; or a pharmaceutically acceptable salt thereof.
• step (1) of Reaction Scheme I a 2,4-dichloro-3-nitroquinoline of Formula X is reacted with an amine of Formula R ⁇ -0-X-NH 2 to provide a 2-chloro-3-nitroquinolin-4- amine of Formula XI.
• the reaction can be carried out by adding the amine to a solution of a compound of Formula X in a suitable solvent such as chloroform or dichloromethane and optionally heating.
• a suitable solvent such as chloroform or dichloromethane and optionally heating.
• Many quinolines of Formula XI are known or can be prepared using known synthetic methods, see for example, Andre et al., U.S. Patent No.4,988,815 and references cited therein.
• Many amines of Formula R ⁇ -O-X-NH 2 are known; some are commercially available and others can by prepared using known synthetic methods.
• step (2) of Reaction Scheme I a 2-chloro-3-nitroquinolin-4-amine of Formula XI is reduced to provide a 2-chloroquinoline-3,4-diamine of Formula XII.
• the reduction is carried out using a conventional heterogeneous hydrogenation catalyst such as platinum on carbon or palladium on carbon.
• the reaction can conveniently be carried out on a Parr apparatus in a suitable solvent such as ethanol, isopropanol or toluene.
• step (3) of Reaction Scheme I a 2-chloroquinoline-3,4-diamine of Formula XII is reacted with a carboxylic acid or an equivalent thereof to provide a 4-chloro-lH- imidazo[4,5-c]quinoline of Formula Xi ⁇ .
• Suitable equivalents to carboxylic acid include orthoesters and 1,1-dialkoxyalkyl alkanoates. The carboxylic acid or equivalent is selected such that it will provide the desired R 2 substituent in a compound of Formula
• triethyl orthoformate will provide a compound where R 2 is hydrogen and triethyl orthoacetate will provide a compound where R 2 is methyl.
• the reaction can be run in the absence of solvent or in an inert solvent such as toluene. The reaction is run with sufficient heating to drive off any alcohol or water formed as a byproduct of the reaction.
• step (3) can be carried out by (i) reacting the diamine of Formula XII with an acyl halide of Formula R 2 C(0)C1 and then (ii) cyclizing.
• the acyl halide is added to a solution of the diamine in an inert solvent such as acetonitrile or dichloromethane.
• the reaction can be carried out at ambient temperature.
• the product can be isolated using conventional methods.
• the product of part (i) is heated in an alcoholic solvent in the presence of a base.
• the product of part (i) is refluxed in ethanol in the presence of an excess of triethylamine or heated with methanolic ammonia.
• a 4-chloro-lH-imidazo[4,5-c]quinoline of Formula XIII is aminated to provide a lH-imidazo[4,5-c]quinolin-4-amine of Formula I.
• the reaction is carried out by heating (e.g.,125-175°C) a compound of Formula XIII under pressure in a sealed reactor in the presence of a solution of ammonia in an alkanol.
• the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
• XIV is protected with a tert-butoxycarbonyl group.
• a solution of the aminoalcohol in tetrahydrofuran is treated with di-tert-butyl dicarbonate in the presence of a base such as sodium hydroxide.
• a base such as sodium hydroxide.
• Many aminoalcohols of Formula XTN are commercially available; others can be prepared using known synthetic methods.
• step (2) of Reaction Scheme II a protected aminoalcohol of Formula XV is converted to an iodide of Formula XVI.
• Iodine is added to a solution of triphenylphosphine and imidazole in dichloromethane; then a solution of a protected aminoalcohol of Formula XV in dichloromethane is added.
• the reaction is carried out at ambient temperature.
• step (3) of Reaction Scheme II a lH-imidazo[4,5-e]quinolin-l-yl alcohol of
• Formula XNII is alkylated with an iodide of Formula XNI to provide a lH-imidazo[4,5- c]quinolin-l-yl ether of Formula XNIII.
• the alcohol of Formula XNII is reacted with sodium hydride in a suitable solvent such as ⁇ , ⁇ -dimethylformamide to form an alkoxide.
• the iodide is added to the alkoxide solution at ambient temperature. After the addition is complete the reaction is stirred at an elevated temperature ( ⁇ 100°C). Many compounds of
• Formula XNII are known, see for example, Gerster, U.S. Patent 4,689,338; others can readily be prepared using known synthetic routes, see for example, Gerster et al., U.S.
• Patent No. 5,605,899 and Gerster U.S. Patent No. 5,175,296.
• step (4) of Reaction Scheme II a lH-imidazo[4,5-c]quinolin-l-yl ether of
• Formula XNIII is oxidized to provide a lH-imidazo[4,5-c]quinoline-5 ⁇ -oxide of Formula
• XIX using a conventional oxidizing agent capable of forming N-oxides.
• a solution of a compound of Formula XNIII in chloroform is oxidized using 3- chloroperoxybenzoic acid at ambient temperature.
• step (5) of Reaction Scheme II a lH-imidazo[4,5-c]quinoline-5 ⁇ -oxide of
• Formula XIX is aminated to provide a lH-imidazo[4,5-c]quinolin-4-amine of Formula
• Step (5) involves (i) reacting a compound of Formula XIX with an acylating agent and then (ii) reacting the product with an animating agent. Part (i) of step (5) involves reacting an N-oxide of Formula XIX with an acylating agent.
• Suitable acylating agents include alkyl- or arylsulfonyl chlorides (e.g., benezenesulfonyl chloride, methanesulfonyl chloride, p-toluenesulfonyl chloride). Arylsulfonyl chlorides are preferred. Para- toluenesulfonyl chloride is most preferred.
• Part (ii) of step (5) involves reacting the product of part (i) with an excess of an aminating agent.
• Suitable aminating agents include ammonia (e.g., in the form of ammonium hydroxide) and ammonium salts (e.g., ammonium carbonate, ammonium bicarbonate, ammonium phosphate).
• Ammonium hydroxide is preferred.
• the reaction is preferably carried out by dissolving the N-oxide of Formula XIX in an inert solvent such as dichloromethane or 1,2-dichloroethane with heating if necessary, adding the aminating agent to the solution, and then slowly adding the acylating agent.
• the reaction can be carried out in a sealed pressure vessel at an elevated temperature (85-100°).
• step (6) of Reaction Scheme II the protecting group is removed by hydrolysis under acidic conditions to provide a lH-imidazo[4,5-c]quinolin-4-amine of Formula XXI.
• the compound of Formula XX is treated with hydrochloric acid ethanol at ambient temperature or with gentle heating.
• step (7) of Reaction Scheme II a lH-imidazo[4,5-c]qumoIm-4-amine of Formula
• XXI is converted to a sulfonamide of Formula XXII which is a subgenus of Formula I using conventional synthetic methods.
• a compound of Formula XXI can be reacted with a sulfonyl chloride of Formula R ⁇ S(O 2 )C ⁇ .
• the reaction can be carried out by adding a solution of the sulfonyl chloride in a suitable solvent such as dichloromethane or l-methyl-2-pyrrolidinone to a solution of a compound of Formula XXI at ambient temperature.
• a compound of Formula XXI can be reacted with a sulfonic anhydride of Formula Ri i S(O 2 )OS(O 2 )R ⁇ ⁇ .
• the reaction can be run at ambient temperature in an inert solvent such as dichloromethane in the presence of a base such as pyridine or N,N-diisopropylethylamine.
• a base such as pyridine or N,N-diisopropylethylamine.
• the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
• step (1) of Reaction Scheme III the amino group of an aminoalcohol of Formula XXIII is protected with a tert-butoxycarbonyl group.
• a solution of the aminoalcohol in tetrahydrofuran is treated with di-tert-butyl dicarbonate in the presence of a base such as sodium hydroxide.
• a base such as sodium hydroxide.
• Many aminoalcohols of Formula XXffl are commercially available; others can be prepared using known synthetic methods.
• step (2) of Reaction Scheme III a protected amino alcohol of Formula XXIN is converted to a methanesulfonate of Formula XXN.
• a solution of a compound of Formula XXIN in a suitable solvent such as dichloromethane is treated with methanesulfonyl chloride in the presence of a base such as triethylamine.
• the reaction can be carried out at a reduced temperature (0°C).
• step (3a) of Reaction Scheme III a methanesulfonate of Formula XXN is converted to an azide of Formula XXNI.
• Sodium azide is added to a solution of a compound of Formula XXN in a suitable solvent such as ⁇ , ⁇ -dimethylformamide or tetrahydrofuran.
• the reaction can be carried out at an elevated temperature (80 - 100°C).
• step (3b) of Reaction Scheme III a compound of Formula XXVI is alkylated with a halide of Formula Hal-R 3 to provide a compound of Formula XXNII. In compounds where R 3 is hydrogen this step is omitted.
• the compound of Formula XXNI is reacted with sodium hydride in a suitable solvent such as ⁇ , ⁇ -dimethylformamide to form the anion and then combined with the halide.
• the reaction can be carried out at ambient temperature.
• step (4) of Reaction Scheme III an azide of Formula XXVI or XXVII is reduced to provide an amine of Formula XXVIII.
• the reduction is carried out using a conventional heterogeneous hydrogenation catalyst such as palladium on carbon.
• the reaction can conveniently be carried out on a Parr apparatus in a suitable solvent such as methanol or isopropanol.
• step (5) of Reaction Scheme III a 4-chloro-3-nitroquinoline of Formula XXIX is reacted with an amine of Formula XXVfll to provide a 3-nitroquinoline of Formula XXX.
• the reaction can be carried out by adding an amine of Formula XXVIII to a solution of a compound of Formula XXIX in a suitable solvent such as dichloromethane in the presence of a base such as triethylamine.
• a base such as triethylamine.
• Many quinolines of Formula XXIX are known compounds or can be prepared using known synthetic methods, see for example, U.S. Patent 4,689,338 and references cited therein.
• step (6) of Reaction Scheme III a 3-nitroquinoline of Formula XXX is reduced to provide a 3-aminoquinoline of Formula XXXI.
• the reduction is carried out using a conventional heterogeneous hydrogenation catalyst such as platinum on carbon.
• step (7) of Reaction Scheme III a compound of Formula XXXI is reacted with a carboxylic acid or an equivalent thereof to provide a lH-imidazo[4,5-c]quinoline of Formula XVIII.
• Suitable equivalents to carboxylic acid include orthoesters, and 1,1- dialkoxyalkyl alkanoates.
• the carboxylic acid or equivalent is selected such that it will provide the desired R 2 substituent in a compound of Formula XVIII. For example, triethyl orthoformate will provide a compound where R 2 is hydrogen and triethyl orthovalerate will provide a compound where R 2 is butyl.
• the reaction can be run in the absence of solvent or in an inert solvent such as toluene.
• the reaction is run with sufficient heating to drive off any alcohol or water formed as a byproduct of the reaction.
• a catalytic amount of pyridine hydrochloride can be included.
• step (7) can be carried out by (i) reacting a compound of Formula XXXI with an acyl halide of Formula R 2 C(0)C1 and then (ii) cyclizing.
• the acyl halide is added to a solution of a compound of Formula XXXI in an inert solvent such as acetonitrile or dichloromethane.
• the reaction can be carried out at ambient temperature or at a reduced temperature.
• the product of part (i) is heated in an alcoholic solvent in the presence of a base.
• the product of part (i) is refluxed in ethanol in the presence of an excess of triethylamine or heated with methanolic ammonia.
• Steps (8), (9), (10) and (11) are carried out in the same manner as steps (4), (5), (6) and (7) of Reaction Scheme II.
• Formula XXI is reacted with sulfuryl chloride to generate in situ a sulfamoyl chloride of Formula XXXII.
• the reaction can be carried out by adding a solution of sulfuryl chloride in dichloromethane to a solution of a compound of Formula XXI in dichloromethane in the presence of 1 equivalent of 4-(dimethylamino)pyridine.
• the reaction is preferably carried out at a reduced temperature (-78°C).
• step (2) of Reaction Scheme IN an amine of Formula H ⁇ RsR ⁇ is reacted with the sulfamoyl chloride of Formula XXXII to provide a sulfamide of Formula XXXIII which is a subgenus of Formula I.
• the reaction can be carried out by adding a solution containing 2 equivalents of the amine and 2 equivalents of triethylamine in dichloromethane to the reaction mixture from step (1).
• the addition is preferably carried out at a reduced temperature (-78°C).
• the reaction mixture can be allowed to warm to ambient temperature.
• the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
• step (1) of Reaction Scheme V a lH-imidazo[4,5-c]quinolin-4-amine of Formula XXI is reduced to provide a 6J,8,9-tetrahydro-lH-imidazo[4,5-c]quinoIin-4- amine of Formula XXXTN.
• the reduction is carried out by suspending or dissolving a compound of Formula XXI in trifluoroacetic acid, adding a catalytic amount of platinum (IN) oxide, and then hydrogenating.
• the reaction can be conveniently carried out in a Parr apparatus.
• Step (2) is carried out in the same manner as step (7) of Reaction Scheme II to provide a 6J,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-4-amine of Formula XXXN which is a subgenus of Formula II.
• the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
• step (1) of Reaction Scheme VI a lH-imidazo[4,5-c]quinolin-4-amine of Formula XXXIV is reacted with sulfuryl chloride to generate in situ a sulfamoyl chloride of Formula XXXVI.
• the reaction can be carried out by adding a solution of sulfuryl chloride in dichloromethane to a solution of a compound of Formula XXXTN in dichloromethane in the presence of 1 equivalent of 4-(dimethylamino)pyridine.
• the reaction is preferably carried out at a reduced temperature (-78°C).
• step (2) of Reaction Scheme VI an amine of Formula HNR 5 R 11 is reacted with the sulfamoyl chloride of Formula XXXVI to provide a sulfamide of Formula XXXVII which is a subgenus of Formula II.
• the reaction can be carried out by adding a solution containing 2 equivalents of the amine and 2 equivalents of triethylamine in dichloromethane to the reaction mixture from step (1).
• the addition is preferably carried out at a reduced temperature (-78°C).
• the reaction mixture can be allowed to warm to ambient temperature.
• the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
• the invention also provides novel compounds useful as intermediates in the synthesis of the compounds of Formulas (I) and (II). These intermediate compounds have the structural Formula (III).
• Ri is selected from the group consisting of: -R 4 -NR 3 -SO 2 -R 6 -alkyl; -R 4 —NR 3 —SO 2 —R 6 — alkenyl;
• R 2 is selected from the group consisting of: -hydrogen; -alkyl; -alkenyl; -aryl;
• Y is -O- or -S(O) 0 -2-;
• R 3 is H, d-io alkyl, or arylalkyl; each Rt is independently alkyl or alkenyl, which may be interrupted by one or more -O- groups; or R 3 and R can join to form a ring;
• each R 5 is independently H, Cwo alkyl, or C 2 - ⁇ o alkenyl;
• Re is a bond, or is alkyl or alkenyl, which may be interrupted by one or more -O- groups;
• R 7 is Ci-io alkyl; or R 3 and R can join together to form a bond;
• n is 0 to 4; and each R present is independently selected from the group consisting of Ci-io alkyl, Ci-io alkoxy, hydroxy, halogen and trif ⁇ uoromethyl; or a pharmaceutically acceptable salt thereof.
• alkyl As used herein, the terms "alkyl”, “alkenyl” and the prefix “alk-” are inclusive of both straight chain and branched chain groups and of cyclic groups, i.e. cycloalkyl and cycloalkenyl. Unless otherwise specified, these groups contain from 1 to 20 carbon atoms, with alkenyl groups containing from 2 to 20 carbon atoms. Preferred groups have a total of up to 10 carbon atoms. Cyclic groups can be monocydic or polycyclic and preferably have from 3 to 10 ring carbon atoms. Exemplary cyclic groups include cyclopropyl, cyclopropylmethyl, cyclopentyl, cyclohexyl and adamantyl.
• alkyl and alkenyl portions of-X- groups can be unsubstituted or substituted by one or more substituents, which substituents are selected from the groups consisting of alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and heterocyclylalkyl.
• substituents are selected from the groups consisting of alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and heterocyclylalkyl.
• haloalkyl is inclusive of groups that are substituted by one or more halogen atoms, including perfluorinated groups. This is also true of groups that include the prefix "halo-". Examples of suitable haloalkyl groups are chloromethyl, trifluoromethyl, and the like.
• aryl as used herein includes carbocyclic aromatic rings or ring systems.
• aryl groups include phenyl, naphthyl, biphenyl, fluorenyl and indenyl.
• heteroaryl includes aromatic rings or ring systems that contain at least one ring hetero atom (e.g., O, S, N). Suitable heteroaryl groups include furyl, thienyl, pyridyl, quinolinyl, isoquinolinyl, indolyl, isoindolyl.
• Heterocyclyl includes non-aromatic rings or ring systems that contain at least one ring hetero atom (e.g., O, S, N) and includes all of the fully saturated and partially unsaturated derivatives of the above mentioned heteroaryl groups.
• exemplary heterocyclic groups include pyrrolidinyl, tetrahydrofuranyl, morpholinyl, thiomorpholinyl, piperidinyl, piperazinyl, thiazolidinyl, imidazolidinyl, and the like.
• the aryl, heteroaryl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, alkylthio, haloalkyl, haloalkoxy, haloalkylthio, halogen, nitro, hydroxy, mercapto, cyano, carboxy, formyl, aryl, aryloxy, arylthio, arylalkoxy, arylalkylthio, heteroaryl, heteroaryloxy, heteroarylthio, heteroarylalkoxy, heteroarylalkylthio, amino, alkylamino, dialkylamino, heterocyclyl, heterocycloalkyl, alkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, haloalkylcarbonyl, haloalkoxycarbonyl, alkylthiocarbonyl, arylcarbonyl, heteroarylcarbon
• preferred Ri groups include —R 4 —NR 3 —SO 2 — Re— alkyl, — P ⁇ — NR 3 — S0 2 — R 6 — aryl, and — R t — NR 3 — S0 2 — Re— heteroaryl wherein the alkyl, aryl and heteroaryl groups can be unsubstituted or substituted and R is preferably ethylene or n-butylene.
• Thiophene and quinoline are preferred heteroaryl groups
• Preferred R 2 groups include hydrogen, alkyl groups having 1 to 4 carbon atoms (i.e., methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl, and cyclopropylmethyl), meth ⁇ xyethyl, and ethoxymethyl.
• substituted groups such as substituted alkyl or substituted aryl groups
• preferred substituents include halogen, nitrile, methoxy, trifluoromethyl, and trifluoromethoxy.
• One or more of these preferred substituents, if present, can be present in the compounds of the invention in any combination.
• the invention is inclusive of the compounds described herein in any of their pharmaceutically acceptable forms, including isomers (e.g., diastereomers and enantiomers), salts, solvates, poiymorphs, and the like.
• isomers e.g., diastereomers and enantiomers
• salts e.g., sodium bicarbonate
• solvates e.g., sodium bicarbonate
• poiymorphs e.g., sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bi
• compositions and Biological Activity contain a therapeutically effective amount of a compound of the invention as described above in combination with a pharmaceutically acceptable carrier.
• a therapeutically effective amount means an amount of the compound sufficient to induce a therapeutic effect, such as cytokine induction, antitumor activity, and/or antiviral activity.
• a therapeutic effect such as cytokine induction, antitumor activity, and/or antiviral activity.
• the exact amount of active compound used in a pharmaceutical composition of the invention will vary according to factors known to those of skill in the art, such as the physical and chemical nature of the compound, the nature of the carrier, and the intended dosing regimen, it is anticipated that the compositions of the invention will contain sufficient active ingredient to provide a dose of about 100 ng/kg to about 50 mg/kg, preferably about 10 ⁇ g/kg to about 5 mg/kg, of the compound to the subject.
• Any of the conventional dosage forms may be used, such as tablets, lozenges, parenteral formulations, syrups, creams, ointments, aerosol formulations, transdermal patches, transmucosal patches and the like.
• the compounds of the invention can be administered as the single therapeutic agent in the treatment regimen, or the compounds of the invention may be administered in combination with one another or with other active agents, including additional immune response modifiers, antivirals, antibiotics, etc.
• the compounds of the invention have been shown to induce the production of certain cytokines in experiments performed according to the tests set forth below. These results indicate that the compounds are useful as immune response modifiers that can modulate the immune response in a number of different ways, rendering them useful in the treatment of a variety of disorders.
• Cytokines whose production may be induced by the administration of compounds according to the invention generally include interferon- ⁇ (IFN- ⁇ ) and/or tumor necrosis factor- ⁇ (TNF- ⁇ ) as well as certain interleukins (IL). Cytokines whose biosynthesis may be induced by compounds of the invention include IFN- ⁇ , TNF- ⁇ , IL-1, IL-6, IL-10 and IL-12, and a variety of other cytokines. Among other effects, these and other cytokines can inhibit virus production and tumor cell growth, making the compounds useful in the treatment of viral diseases and tumors. Accordingly, the invention provides a method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or composition of the invention to the animal.
• Certain compounds of the invention have been found to preferentially induce the expression of IFN- ⁇ in a population of hematopoietic cells such as PBMCs (peripheral blood mononuclear cells) containing pDC2 cells (precursor dendritic cell-type 2) without concomitant production of significant levels of inflammatory cytokines.
• PBMCs peripheral blood mononuclear cells
• pDC2 cells precursor dendritic cell-type 2
• the compounds of the invention affect other aspects of the innate immune response. For example, natural killer cell activity may be stimulated, an effect that may be due to cytokine induction.
• the compounds may also activate macrophages, which in turn stimulates secretion of nitric oxide and the production of additional cytokines. Further, the compounds may cause proliferation and differentiation of B-lymphocytes.
• Compounds of the invention also have an effect on the acquired immune response.
• the production of the T helper type 1 (Thl) cytokine IFN- ⁇ is induced indirectly and the production of the T helper type 2 (Th2) cytokines IL-4, IL-5 and IL-13 are inhibited upon administration of the compounds.
• This activity means that the compounds are useful in the treatment of diseases where upregulation of the Thl response and/or downregulation of the Th2 response is desired.
• the compounds are expected to be useful in the treatment of atopic diseases, e.g., atopic dermatitis, asthma, allergy, allergic rhinitis; systemic lupus erythernatosis; as a vaccine adjuvant for cell mediated immunity; and possibly as a treatment for recurrent fungal diseases and chlamydia.
• atopic diseases e.g., atopic dermatitis, asthma, allergy, allergic rhinitis; systemic lupus erythernatosis; as a vaccine adjuvant for cell mediated immunity; and possibly as a treatment for recurrent fungal diseases and chlamydia.
• the immune response modifying effects of the compounds make them useful in the treatment of a wide variety of conditions. Because of their ability to induce the production of cytokines such as IFN- ⁇ and/or TNF- ⁇ , the compounds are particularly useful in the treatment of viral diseases and tumors. This immunomodulating activity suggests that compounds of the invention are useful
• Hepatitis C Herpes Simplex Virus Type I and Type II; molluscum contagiosum; variola, particularly variola major; HIV; CMV; NZV; rhinovirus; adenovirus; influenza; and para-influenza; intraepithelial neoplasias such as cervical intraepithelial neoplasia; human papillomavirus (HPV) and associated neoplasias; fungal diseases, e.g.
• Candida aspergillus, and cryptococcal meningitis
• neoplastic diseases e.g., basal cell carcinoma, hairy cell leukemia, Kaposi's sarcoma, renal cell carcinoma, squamous cell carcinoma, myelogenous leukemia, multiple myeloma, melanoma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, and other cancers
• parasitic diseases e.g., basal cell carcinoma, hairy cell leukemia, Kaposi's sarcoma, renal cell carcinoma, squamous cell carcinoma, myelogenous leukemia, multiple myeloma, melanoma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, and other cancers
• parasitic diseases e.g.
• Additional diseases or conditions that can be treated using the compounds of the invention include actinic keratosis; eczema; eosinophilia; essential thrombocythaemia; leprosy; multiple sclerosis; Ommen's syndrome; discoid lupus; Bowen's disease; Bowenoid papulosis; alopecia areata; the inhibition of keloid formation after surgery and other types of post-surgical scars.
• these compounds could enhance or stimulate the healing of wounds, including chronic wounds.
• the compounds may be useful for treating the opportunistic infections and tumors that occur after suppression of cell mediated immunity in, for example, transplant patients, cancer patients and HIN patients.
• An amount of a compound effective to induce cytokine biosynthesis is an amount sufficient to cause one or more cell types, such as monocytes, macrophages, dendritic cells and B-cells, to produce an amount of one or more cytokines such as, for example, IF ⁇ - ⁇ , T ⁇ F- ⁇ , IL-1, IL-6, IL-10 and IL-12 that is increased over the background level of such cytokines.
• the precise amount will vary according to factors known in the art but is expected to be a dose of about 100 ng/kg to about 50 mg/kg, preferably about 10 ⁇ gkg to about 5 mg/kg.
• the invention also provides a method of treating a viral infection in an animal and a method of treating a neoplastic disease in an animal comprising administering an effective amount of a compound or composition of the invention to the animal.
• An amount effective to treat or inhibit a viral mfection is an amount that will cause a reduction in one or more of the manifestations of viral infection, such as viral lesions, viral load, rate of virus production, and mortality as compared to untreated control animals.
• the precise amount will vary according to factors known in the art but is expected to be a dose of about 100 ng/kg to about 50 mg/kg, preferably about 10 ⁇ g/kg to about 5 mg/kg.
• An amount of a compound effective to treat a neoplastic condition is an amount that will cause a reduction in tumor size or in the number of tumor foci. Again, the precise amount will vary according to factors known in the art but is expected to be a dose of about 100 ng/kg to about 50 mgkg, preferably about 10 ⁇ g/kg to about 5 mg/kg.
• the invention is further described by the following examples, which are provided for illustration only and are not intended to be limiting in any way.
• Sodium hydride (60% oil dispersion, 9.1 g, 228 mmol) was placed in a round bottom flask and washed with hexanes (3X) under N 2 .
• the dried sodium hydride was treated with 800 mL of anhydrous T ⁇ F.
• a solution of tert-butyl 2-(2- azidoethoxy)ethylcarbamate (41.9 g, 182 mmol) in 200 mL of T ⁇ F was then added to the stirred sodium hydride solution over 40 min. After addition was complete, the reaction was stirred an additional 20 min followed by addition of methyl iodide (13.6 mL, 218 mmol).
• the free base was made by dissolving the hydrochloride salt in 50 mL of ⁇ 2 0 and treating with 5 mL of concentrated NEL t OH. The aqueous suspension was extracted with CHC1 3 (5 X 50 mL). The combined organic layers were dried over Na 2 SO 4 and concentrated to give 3.93 g of 2-(2-methoxyethyI)-l- ⁇ 2-[2- (methylamino)ethoxy]ethyl ⁇ -lH-imidazo[4,5-c]quinolin-4-amine as a tan powder. MS 344 (M + ⁇ ) + ; ⁇ NMR (300 MHz, DMSO-t .
• the yellow oil was dissolved in 50 mL of H 0 and extracted with 50 mL of CHC1 3 . The organic portion was removed and discarded. The aqueous portion was then made basic (pH ⁇ 12) by addition of 10% ⁇ aOH solution. This was then extracted with CHC1 3 (6 X 50 mL) and the combined organic layers were dried over ⁇ a 2 SO 4 and concentrated to a brown oil. The brown oil was dissolved in 100 mL of hot MeOH and treated with 1 g of activated charcoal. The hot solution was filtered through Celite and concentrated to dryness.
• chloropropylsulfonyl chloride (0.05 ml, 0.46 mmol) was added dropwise to a solution of l-[2-(2-aminoethoxy)ethyl]-2-butyl-lH-imidazo[4,5- c]quinolin-4-amine (0J2 g, 0.37 mmol) and triethylamine (0.065 ml, 0.46 mmol) in dichloromethane (5 ml). The reaction was stirred for 20 hours followed by removal of the solvent in vacuo.
• Part B A solution of tert-butyl 2-[2-(2-butyl- 1 H-imidazo[4,5-c]quinolin- 1 - yl)ethoxy]ethylcarbamate (4.12 g, 10.0 mmol) in 50 mL of CH 2 C1 2 was treated with 3- chloroperoxybenzoic acid (MCPBA, 77%, 2.5 g, 11.2 mmol). After stirring for 5 h, the reaction mixture was treated with saturated NaHCO 3 solution and the layers were separated.
• MCPBA 3- chloroperoxybenzoic acid
• the sulfonyl chloride or the sulfamoyl chloride (1.1 eq.) was added to a test tube containing a solution of l-[2-(2-aminoethoxy)ethyl]-2-butyl-lH-imidazo[4,5-c]quinolin-4- amine (25 mg) in dichloromethane (5 mL).
• the test tube was capped and then placed on a shaker at ambient temperature for 18 - 20 hr.
• the solvent was removed by vacuum centrifugation.
• the residue was purified by semi-preparative ⁇ PLC using the method described above.
• the products were verified by accurate mass and ⁇ NMR.
• the table below shows the structure of the free base and the observed accurate mass (M + ⁇ ).
• This material was purified by column chromatography (silica gel eluting first with 50% ethyl acetate in hexanes and then with ethyl acetate) to provide 1.0 g of tert-butyl 4- ⁇ 2-[2-(4-amino-lH-imidazo[4,5-c]quinolin-l- yl)butoxy]ethyl ⁇ piperidine-l-carboxylate as pale yellow glassy foam.
• tert-butyl 4- ⁇ 2-[2-(4-amino-lH-imidazo[4,5- c]quinolin-l-yl)butoxy]ethyl ⁇ piperidine-l-carboxylate (1.00 g, 2.1 mmol) and 2N ethanolic hydrochloric acid (10 ml, 20 mmol) were combined and the solution was stirred at ambient temperature for 14 hours. The solvent was removed in vacuo and the resulting tan solid was dissolved in water. Saturated aqueous sodium carbonate was added until the p ⁇ reached 10.
• the oil was purified by column chromatography (silica gel eluting with acetonitrile containing increasing amounts of ethanol) to provide 4.6 g of N- (10-amino-4J-dioxadecyl)-5-dimethylaminona ⁇ hthalene-l-sulfonamide as a viscous oil.
• the crude salt from Part D was dissolved in dry methanol containing 7% ammonia (20 mL). The solution was heated at 150°C in a bomb for 6 1/2 hrs. The reaction mixture was cooled and then concentrated. The residue was combined with acetone. Undissolved material was removed by filtration. The filtrate was concentrated and the residue was purified by column chromatography (silica gel; ethanol/dichloromethane) to provide 0.45 g of a brown oil.
• This material was then purified by high performance liquid chromatography using a Bondapak C18 12.5 nm reverse phase column (available from Waters, Milford, MA) eluting with a composite gradient of acetonitrile in water to provide the desired product.
• Bondapak C18 12.5 nm reverse phase column available from Waters, Milford, MA
• CYTOKINE INDUCTION IN HUMAN CELLS An in vitro human blood cell system is used to assess cytokine induction. Activity is based on the measurement of interferon and tumor necrosis factor ( ⁇ ) (IFN and TNF, respectively) secreted into culture media as described by Testerman et. al. In “Cytokine Induction by the Immunomodulators Imiquimod and S-27609", Journal of Leukocyte Biology, 58, 365-372 (September, 1995). Blood Cell Preparation for Culture
• PBMCs Peripheral blood mononuclear cells
• Histopaque®-1077 The PBMCs are washed twice with Hank's Balanced Salts Solution and then are suspended at 3-4 x 10 6 cells/mL in RPMI complete.
• the PBMC suspension is added to 48 well flat bottom sterile tissue culture plates (Costar, Cambridge, MA or Becton Dickinson Labware, Lincoln Park, NJ) containing an equal volume of RPMI complete media containing test compound.
• the compounds are solubilized in dimethyl sulfoxide (DMSO).
• DMSO concentration should not exceed a final concentration of 1% for addition to the culture wells. Incubation
• test compound is added to the first well containing RPMI complete and serial dilutions are made in the wells.
• the PBMC suspension is then added to the wells in an equal volume, bringing the test compound concentrations to the desired range.
• the final concentration of PBMC suspension is 1.5-2 X 10 6 cells/mL.
• the plates are covered with sterile plastic lids, mixed gently and then incubated for 18 to 24 hours at 37°C in a 5% carbon dioxide atmosphere.
• Interferon- ⁇ concentration is determined by ELISA using a Human Multi-Species kit from PBL Biomedical Laboratories, New Brunswick, NJ. Results are expressed in pg/mL.
• Tumor necrosis factor- ⁇ concentration is determined using ELISA kits available from Genzyme, Cambridge, MA; R&D Systems, Minneapolis, MN; or Pharmingen, San Diego, CA. Results are expressed in pg/mL.
• the table below lists the lowest concentration found to induce interferon and the lowest concentration found to induce tumor necrosis factor for each compound. A "*" indicates that no induction was seen at any of the tested concentrations; generally the highest concentration tested was 10 or 30 ⁇ M.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Virology (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Immunology (AREA)
• Molecular Biology (AREA)
• Pulmonology (AREA)
• Tropical Medicine & Parasitology (AREA)
• Dermatology (AREA)
• Biomedical Technology (AREA)
• Neurosurgery (AREA)
• Neurology (AREA)
• Biotechnology (AREA)
• Hematology (AREA)
• Epidemiology (AREA)
• Psychiatry (AREA)
• Reproductive Health (AREA)
• AIDS & HIV (AREA)
• Pain & Pain Management (AREA)
• Rheumatology (AREA)
• Ophthalmology & Optometry (AREA)
• Endocrinology (AREA)
• Diabetes (AREA)
• Gastroenterology & Hepatology (AREA)
• Transplantation (AREA)
• Hospice & Palliative Care (AREA)

Priority Applications (21)

Applications Claiming Priority (2)

Publications (2)

Family

ID=22963391

Family Applications (6)

Family Applications After (5)

Country Status (31)

Cited By (39)

Families Citing this family (170)

Family Cites Families (103)

• 2001
  • 2001-06-12 UA UA2003065277A patent/UA75622C2/uk unknown
  • 2001-06-12 UA UA2003065275A patent/UA74852C2/uk unknown
  • 2001-12-06 WO PCT/US2001/046582 patent/WO2002046190A2/en not_active Ceased
  • 2001-12-06 HU HU0600605A patent/HUP0600605A2/hu unknown
  • 2001-12-06 CN CNB018201598A patent/CN1247575C/zh not_active Expired - Fee Related
  • 2001-12-06 MX MXPA03004973A patent/MXPA03004973A/es not_active Application Discontinuation
  • 2001-12-06 HU HU0400704A patent/HUP0400704A2/hu unknown
  • 2001-12-06 CN CNB018201679A patent/CN1297554C/zh not_active Expired - Fee Related
  • 2001-12-06 KR KR10-2003-7007539A patent/KR20040047733A/ko not_active Withdrawn
  • 2001-12-06 DE DE60117859T patent/DE60117859T2/de not_active Expired - Fee Related
  • 2001-12-06 MX MXPA03005012A patent/MXPA03005012A/es active IP Right Grant
  • 2001-12-06 CN CNB01820161XA patent/CN1253452C/zh not_active Expired - Fee Related
  • 2001-12-06 MX MXPA03004974A patent/MXPA03004974A/es active IP Right Grant
  • 2001-12-06 DE DE60126645T patent/DE60126645T2/de not_active Expired - Fee Related
  • 2001-12-06 KR KR10-2003-7007537A patent/KR20030070050A/ko not_active Withdrawn
  • 2001-12-06 WO PCT/US2001/046697 patent/WO2002046192A2/en not_active Ceased
  • 2001-12-06 AU AU2002232497A patent/AU2002232497B2/en not_active Ceased
  • 2001-12-06 EP EP01992005A patent/EP1341792A2/en not_active Withdrawn
  • 2001-12-06 SI SI200130720T patent/SI1341790T1/sl unknown
  • 2001-12-06 KR KR10-2003-7007532A patent/KR20040023576A/ko not_active Withdrawn
  • 2001-12-06 EE EEP200300274A patent/EE200300274A/xx unknown
  • 2001-12-06 SK SK712-2003A patent/SK7122003A3/sk unknown
  • 2001-12-06 AU AU3953002A patent/AU3953002A/xx active Pending
  • 2001-12-06 JP JP2002547927A patent/JP2004529078A/ja active Pending
  • 2001-12-06 PL PL366330A patent/PL207340B1/pl not_active IP Right Cessation
  • 2001-12-06 HR HR20030462A patent/HRP20030462A2/xx not_active Application Discontinuation
  • 2001-12-06 CZ CZ20031561A patent/CZ20031561A3/cs unknown
  • 2001-12-06 CZ CZ20031562A patent/CZ20031562A3/cs unknown
  • 2001-12-06 SK SK684-2003A patent/SK6842003A3/sk not_active Application Discontinuation
  • 2001-12-06 BR BR0116470-8A patent/BR0116470A/pt not_active IP Right Cessation
  • 2001-12-06 JP JP2002547929A patent/JP2004515500A/ja not_active Withdrawn
  • 2001-12-06 IL IL15588401A patent/IL155884A0/xx unknown
  • 2001-12-06 AU AU2002230618A patent/AU2002230618B2/en not_active Ceased
  • 2001-12-06 EP EP01987283A patent/EP1341790B1/en not_active Expired - Lifetime
  • 2001-12-06 MX MXPA03004975A patent/MXPA03004975A/es active IP Right Grant
  • 2001-12-06 ES ES01992018T patent/ES2260323T3/es not_active Expired - Lifetime
  • 2001-12-06 KR KR10-2003-7007538A patent/KR20040028691A/ko not_active Withdrawn
  • 2001-12-06 CA CA2436980A patent/CA2436980C/en not_active Expired - Fee Related
  • 2001-12-06 PL PL01365995A patent/PL365995A1/xx unknown
  • 2001-12-06 ES ES01987283T patent/ES2281456T3/es not_active Expired - Lifetime
  • 2001-12-06 PL PL01365907A patent/PL365907A1/xx not_active Application Discontinuation
  • 2001-12-06 DE DE60111076T patent/DE60111076T2/de not_active Expired - Lifetime
  • 2001-12-06 EP EP01987297A patent/EP1341791B1/en not_active Expired - Lifetime
  • 2001-12-06 HR HR20030464A patent/HRP20030464A2/hr not_active Application Discontinuation
  • 2001-12-06 KR KR10-2003-7007535A patent/KR20040028690A/ko not_active Withdrawn
  • 2001-12-06 AT AT01987283T patent/ATE353895T1/de not_active IP Right Cessation
  • 2001-12-06 PT PT01987297T patent/PT1341791E/pt unknown
  • 2001-12-06 US US10/013,060 patent/US6656938B2/en not_active Expired - Fee Related
  • 2001-12-06 DK DK01987297T patent/DK1341791T3/da active
  • 2001-12-06 RU RU2003116060/04A patent/RU2302418C2/ru active
  • 2001-12-06 AU AU2002239516A patent/AU2002239516B2/en not_active Ceased
  • 2001-12-06 DK DK01987283T patent/DK1341790T3/da active
  • 2001-12-06 KR KR10-2003-7007534A patent/KR20030070049A/ko not_active Abandoned
  • 2001-12-06 IL IL15590301A patent/IL155903A0/xx unknown
  • 2001-12-06 AU AU2002239530A patent/AU2002239530B2/en not_active Ceased
  • 2001-12-06 RU RU2003116059/04A patent/RU2308456C2/ru not_active IP Right Cessation
  • 2001-12-06 IL IL15595001A patent/IL155950A0/xx unknown
  • 2001-12-06 AU AU3061802A patent/AU3061802A/xx active Pending
  • 2001-12-06 AU AU3951702A patent/AU3951702A/xx active Pending
  • 2001-12-06 CA CA2436846A patent/CA2436846C/en not_active Expired - Fee Related
  • 2001-12-06 AT AT01992018T patent/ATE319711T1/de not_active IP Right Cessation
  • 2001-12-06 HR HR20030461A patent/HRP20030461A2/hr not_active Application Discontinuation
  • 2001-12-06 BR BRPI0116052-4A patent/BR0116052A/pt not_active Application Discontinuation
  • 2001-12-06 CA CA002430844A patent/CA2430844A1/en not_active Withdrawn
  • 2001-12-06 JP JP2002547926A patent/JP2004523498A/ja active Pending
  • 2001-12-06 DK DK01992018T patent/DK1343784T3/da active
  • 2001-12-06 SK SK713-2003A patent/SK287732B6/sk not_active IP Right Cessation
  • 2001-12-06 JP JP2002547928A patent/JP2004521092A/ja not_active Ceased
  • 2001-12-06 CA CA002431151A patent/CA2431151A1/en not_active Withdrawn
  • 2001-12-06 CZ CZ20031560A patent/CZ295848B6/cs not_active IP Right Cessation
  • 2001-12-06 AU AU3951602A patent/AU3951602A/xx active Pending
  • 2001-12-06 US US10/012,599 patent/US6683088B2/en not_active Expired - Fee Related
  • 2001-12-06 WO PCT/US2001/046696 patent/WO2002046191A2/en not_active Ceased
  • 2001-12-06 EE EEP200300270A patent/EE200300270A/xx unknown
  • 2001-12-06 HR HR20030466A patent/HRP20030466A2/hr not_active Application Discontinuation
  • 2001-12-06 ES ES01987297T patent/ES2242782T3/es not_active Expired - Lifetime
  • 2001-12-06 JP JP2002547925A patent/JP4437189B2/ja not_active Expired - Fee Related
  • 2001-12-06 BR BR0116026-5A patent/BR0116026A/pt not_active IP Right Cessation
  • 2001-12-06 CZ CZ20031591A patent/CZ20031591A3/cs unknown
  • 2001-12-06 US US10/013,202 patent/US6670372B2/en not_active Expired - Fee Related
  • 2001-12-06 WO PCT/US2001/046581 patent/WO2002046189A2/en not_active Ceased
  • 2001-12-06 HU HU0600338A patent/HUP0600338A2/hu active IP Right Revival
  • 2001-12-06 CA CA002436984A patent/CA2436984A1/en not_active Abandoned
  • 2001-12-06 PT PT01987283T patent/PT1341790E/pt unknown
  • 2001-12-06 PL PL01361948A patent/PL361948A1/xx not_active Application Discontinuation
  • 2001-12-06 BR BR0116047-8A patent/BR0116047A/pt not_active IP Right Cessation
  • 2001-12-06 CZ CZ20031592A patent/CZ303462B6/cs not_active IP Right Cessation
  • 2001-12-06 SK SK715-2003A patent/SK7152003A3/sk unknown
  • 2001-12-06 EP EP01990852A patent/EP1339715A2/en not_active Withdrawn
  • 2001-12-06 NZ NZ526086A patent/NZ526086A/en unknown
  • 2001-12-06 RU RU2003116061/04A patent/RU2315049C2/ru not_active IP Right Cessation
  • 2001-12-06 HU HU0700062A patent/HUP0700062A2/hu active IP Right Revival
  • 2001-12-06 SK SK710-2003A patent/SK287264B6/sk not_active IP Right Cessation
  • 2001-12-06 WO PCT/US2001/046704 patent/WO2002046193A2/en not_active Ceased
  • 2001-12-06 SK SK711-2003A patent/SK7112003A3/sk unknown
  • 2001-12-06 EP EP01992018A patent/EP1343784B1/en not_active Expired - Lifetime
  • 2001-12-06 BR BRPI0116464-3A patent/BR0116464A/pt not_active IP Right Cessation
  • 2001-12-06 NZ NZ526088A patent/NZ526088A/xx unknown
  • 2001-12-06 IL IL15604401A patent/IL156044A0/xx unknown
  • 2001-12-06 JP JP2002547930A patent/JP2004515501A/ja active Pending
  • 2001-12-06 EE EEP200300272A patent/EE200300272A/xx unknown
  • 2001-12-06 CN CNA018201687A patent/CN1479739A/zh active Pending
  • 2001-12-06 IL IL15604301A patent/IL156043A0/xx unknown
  • 2001-12-06 CN CNA018201725A patent/CN1894244A/zh active Pending
  • 2001-12-06 RU RU2003116063/04A patent/RU2003116063A/ru not_active Application Discontinuation
  • 2001-12-06 HU HU0600600A patent/HUP0600600A2/hu unknown
  • 2001-12-06 HR HR20030463A patent/HRP20030463A2/xx not_active Application Discontinuation
  • 2001-12-06 MX MXPA03005011A patent/MXPA03005011A/es active IP Right Grant
  • 2001-12-06 HR HR20030467A patent/HRP20030467B1/xx not_active IP Right Cessation
  • 2001-12-06 EE EEP200300268A patent/EE200300268A/xx unknown
  • 2001-12-06 CZ CZ20031563A patent/CZ20031563A3/cs unknown
  • 2001-12-06 HU HU0400710A patent/HUP0400710A2/hu unknown
  • 2001-12-06 AU AU3248202A patent/AU3248202A/xx active Pending
  • 2001-12-06 BR BRPI0116032-0A patent/BR0116032A/pt not_active IP Right Cessation
  • 2001-12-06 NZ NZ526089A patent/NZ526089A/en unknown
  • 2001-12-06 CA CA002436983A patent/CA2436983A1/en not_active Abandoned
  • 2001-12-06 NZ NZ526087A patent/NZ526087A/en unknown
  • 2001-12-06 NZ NZ526105A patent/NZ526105A/en unknown
  • 2001-12-06 EE EEP200300275A patent/EE200300275A/xx unknown
  • 2001-12-06 CN CNB018199070A patent/CN1252070C/zh not_active Expired - Fee Related
  • 2001-12-06 AU AU2002232482A patent/AU2002232482B2/en not_active Ceased
  • 2001-12-06 RU RU2003116649/04A patent/RU2351598C2/ru not_active IP Right Cessation
  • 2001-12-06 AU AU3249702A patent/AU3249702A/xx active Pending
  • 2001-12-06 EE EEP200300271A patent/EE200300271A/xx unknown
  • 2001-12-06 PL PL01365883A patent/PL365883A1/xx not_active Application Discontinuation
  • 2001-12-06 EP EP01987282A patent/EP1341789A2/en not_active Ceased
  • 2001-12-06 NZ NZ526106A patent/NZ526106A/en not_active IP Right Cessation
  • 2001-12-06 PL PL392462A patent/PL392462A1/pl unknown
  • 2001-12-06 MX MXPA03004972A patent/MXPA03004972A/es active IP Right Grant
  • 2001-12-06 AU AU2002239517A patent/AU2002239517B2/en not_active Ceased
  • 2001-12-06 WO PCT/US2001/046359 patent/WO2002046188A2/en not_active Ceased
  • 2001-12-06 PL PL01366115A patent/PL366115A1/xx not_active Application Discontinuation
  • 2001-12-06 RU RU2003116123/04A patent/RU2003116123A/ru not_active Application Discontinuation
  • 2001-12-06 IL IL15590401A patent/IL155904A0/xx unknown
  • 2001-12-06 AT AT01987297T patent/ATE296301T1/de active
  • 2001-12-07 TW TW090130402A patent/TWI222972B/zh active
  • 2001-12-07 TW TW090130401A patent/TW584633B/zh not_active IP Right Cessation
  • 2001-12-07 TW TW090130404A patent/TWI293300B/zh active
  • 2001-12-10 AR ARP010105727A patent/AR035665A1/es unknown
  • 2001-12-10 AR ARP010105726A patent/AR035664A1/es active IP Right Grant
  • 2001-12-10 AR ARP010105730A patent/AR035668A1/es unknown
  • 2001-12-10 AR ARP010105731A patent/AR035669A1/es unknown
  • 2001-12-10 AR ARP010105728A patent/AR035666A1/es unknown
  • 2001-12-10 AR ARP010105729A patent/AR035667A1/es unknown
• 2003
  • 2003-05-28 NO NO20032449A patent/NO20032449L/no not_active Application Discontinuation
  • 2003-05-28 NO NO20032451A patent/NO20032451L/no not_active Application Discontinuation
  • 2003-05-28 NO NO20032452A patent/NO20032452L/no not_active Application Discontinuation
  • 2003-05-30 NO NO20032473A patent/NO326159B1/no not_active IP Right Cessation
  • 2003-06-06 NO NO20032595A patent/NO20032595D0/no not_active Application Discontinuation
  • 2003-06-06 NO NO20032596A patent/NO20032596L/no not_active Application Discontinuation
  • 2003-07-08 ZA ZA200305273A patent/ZA200305273B/en unknown
  • 2003-07-08 ZA ZA200305275A patent/ZA200305275B/en unknown
  • 2003-07-08 ZA ZA200305271A patent/ZA200305271B/en unknown
  • 2003-07-08 ZA ZA200305270A patent/ZA200305270B/en unknown
  • 2003-07-08 ZA ZA200305274A patent/ZA200305274B/en unknown
  • 2003-07-08 ZA ZA2003/05272A patent/ZA200305272B/en unknown
  • 2003-10-07 US US10/680,989 patent/US7049439B2/en not_active Expired - Fee Related
  • 2003-10-29 US US10/696,476 patent/US20040092545A1/en not_active Abandoned
  • 2003-10-29 US US10/696,753 patent/US6953804B2/en not_active Expired - Fee Related
• 2005
  • 2005-02-28 US US11/069,033 patent/US7132429B2/en not_active Expired - Fee Related
  • 2005-05-19 US US11/132,900 patent/US7612083B2/en not_active Expired - Fee Related
  • 2005-08-24 CY CY20051101024T patent/CY1105586T1/el unknown
• 2007
  • 2007-05-09 CY CY20071100621T patent/CY1106569T1/el unknown
• 2009
  • 2009-11-06 JP JP2009255040A patent/JP2010031040A/ja not_active Ceased